glp 1 weight loss zepbound WE HAVE DONE IT! 🎊🥂🥳, #glp1 #beforeandafterweightloss #beforeandafter Zepbound Helped Type 1 Diabetes

Common side effects, especially early in treatment, can include nausea (which often diminishes as the body adjusts), vomiting, diarrhea or constipation, decreased appetite, and injection site reactions

NuraPatch is not FDA-approved as a prescription drug

Scandinavian Journal of Work, Environment & Health 2000

Our Research Lead examined anonymized platform data from: 5,864 US adults using tirzepatide (Mounjaro or Zepbound) 4,456 US adults using semaglutide (Ozempic or Wegovy) Inclusion criteria: Active GLP-1 therapy with weekly injections Minimum 12-week tracking duration Adherence threshold: 1 injection log and 1 weight entry per week No weight entries outside physiological bounds (30300 kg) or with weekly changes exceeding 5% Primary outcome: Percentage body weight change from baseline, calculated as [(current weight baseline weight) / baseline weight] 100 , where negative values indicate weight loss Data collection period: Data were collected from all available platform records through January 2026, representing naturalistic use patterns without researcher intervention